MVA and NYVAC as vaccines against emergent infectious diseases and cancer

Current Gene Therapy

Volumn 11, Issue 3, 2011, Pages 189-217

  Gómez, Carmen E ^a   Nájera, José L ^a   Krupa, Magdalena ^a   Perdiguero, Beatriz ^a   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Clinical; Mva and nyvac; Pathogens; Poxvirus vectors; Preclinical; Tumours; Vaccines

Indexed keywords

ATTENUATED VACCINIA VIRUS CANINE DISTEMPER VIRUS VACCINE; ATTENUATED VACCINIA VIRUS JAPANESE ENCEPHALITIS VIRUS VACCINE; ATTENUATED VACCINIA VIRUS RABIES GLYCOPROTEIN VACCINE; ATTENUATED VACCINIA VIRUS VACCINE; ATTENUATED VACCINIA VIRUS VECTOR; BCG VACCINE; MODIFIED VACCINIA VIRUS ANKARA 85 A VACCINE; MODIFIED VACCINIA VIRUS ANKARA CYTOMEGALOVIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA DENGUE TYPE 2 VACCINE; MODIFIED VACCINIA VIRUS ANKARA DENGUE TYPE 4 VACCINE; MODIFIED VACCINIA VIRUS ANKARA FUSION PROTEIN VACCINE; MODIFIED VACCINIA VIRUS ANKARA GB680 VACCINE; MODIFIED VACCINIA VIRUS ANKARA GLYCOPROTEIN C VACCINE; MODIFIED VACCINIA VIRUS ANKARA HEMAGGLUTININ GLYCOPROTEIN VACCINE; MODIFIED VACCINIA VIRUS ANKARA HEPATITIS C VIRUS TG4040 VACCINE; MODIFIED VACCINIA VIRUS ANKARA IMMEDIATE EARLY GENE VACCINE; MODIFIED VACCINIA VIRUS ANKARA JAPANESE ENCEPHALITIS VIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA NUCLEOCAPSID PROTEIN VACCINE; MODIFIED VACCINIA VIRUS ANKARA NUCLEOPROTEIN VACCINE; MODIFIED VACCINIA VIRUS ANKARA PROTEIN E1E2 VACCINE; MODIFIED VACCINIA VIRUS ANKARA RABIES GLYCOPROTEIN VACCINE; MODIFIED VACCINIA VIRUS ANKARA RESPIRATORY SYNCTIAL VIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA RESPIRATORY SYNCYTIAL VIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA SPIKE GLYCOPROTEIN VACCINE; MODIFIED VACCINIA VIRUS ANKARA TEGUMENT PROTEIN VACCINE; MODIFIED VACCINIA VIRUS ANKARA VACCINE; MODIFIED VACCINIA VIRUS ANKARA VIRUS VECTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE; VIRUS VECTOR;

ARTICLE; CANINE DISTEMPER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CYTOMEGALOVIRUS INFECTION; DENGUE; DISEASE MODEL; ELECTRON MICROSCOPY; ENZYME INHIBITION; EQUINE INFLUENZA; GENE DELETION; GENE EXPRESSION; HELA CELL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOMODULATION; INFLUENZA A (H1N1); JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MEASLES; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POXVIRUS; RABIES; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RNA SPLICING; SEVERE ACUTE RESPIRATORY SYNDROME; SWINE INFLUENZA; TUBERCULOSIS; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ANIMALIA; POXVIRIDAE; VACCINIA VIRUS ANKARA;

EID: 79958226287     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652311795684731     Document Type: Article

References (299)

1. Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 1982; 79(23): 7415-7419
2. Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A 1982; 79(16): 4927-49231.
3. Moss B. Vaccinia virus: a tool for research and vaccine development. Science 1991; 252(5013): 1662-1667.
4. Mackett M, Smith GL. Vaccinia virus expression vectors. J Gen Virol 1986; 67 (Pt 10): 2067-2082.
5. Pastoret PP, Vanderplasschen A. Poxviruses as vaccine vectors. Comp Immunol Microbiol Infect Dis 2003; 26(5-6): 343-355.
6. Collier LH. The development of a stable smallpox vaccine. J Hyg (Lond) 1955; 53(1): 76-101.
7. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med 1969; 281(22): 1201-1208.
8. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987; 316(11): 673-676.
9. Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 2003; 3(3): 263-271.
10. Hochstein-Mintzel V. [Oral and nasal immunization with Poxvirus vacciniae. I. Criteria for smallpox immunity and immunology of the conventional cutaneous reaction to vaccination]. Zentralbl Bakteriol [Orig B] 1972; 156(1): 1-14.
11. Mayr A, Stickl H, Muller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol [B] 1978; 167(5-6): 375-390.
12. McCurdy LH, Larkin BD, Martin JE, Graham BS. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin Infect Dis 2004; 38(12): 1749-1753.
13. Drexler I, Staib C, Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 2004; 15(6): 506-512.
14. Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998; 244(2): 365-396.
15. Sancho MC, Schleich S, Griffiths G, Krijnse-Locker J. The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis. J Virol 2002; 76(16): 8318-8334.
16. Gallego-Gomez JC, Risco C, Rodriguez D, et al. Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J Virol 2003; 77(19): 10606-10622.
17. Tartaglia J, Perkus ME, Taylor J, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992; 188(1): 217-232.
18. Perkus ME, Tartaglia J, Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol 1995; 58(1): 1-13.
19. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 1996; 93(21): 11349-1353.
20. Hanke T, McMichael AJ, Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 2007; 88(Pt 1): 1-12.
21. Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, Paoletti E. The complete DNA sequence of vaccinia virus. Virology 1990; 179(1): 247-66, 517-563.
22. Upton C, Slack S, Hunter AL, Ehlers A, Roper RL. Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome. J Virol 2003; 77(13): 7590-7600.
23. Najera JL, Gomez CE, Domingo-Gil E, Gherardi MM, Esteban M. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol 2006; 80(12): 6033-6047.
24. Gomez CE, Najera JL, Domingo-Gil E, Ochoa-Callejero L, Gonzalez- Aseguinolaza G, Esteban M. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J Gen Virol 2007; 88(Pt 9): 2473-248.
25. Backes S, Sperling KM, Zwilling J, et al. Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2alpha. J Gen Virol 2010; 91(Pt 2): 470-482.
26. Willis KL, Patel S, Xiang Y, Shisler JL. The effect of the vaccinia K1 protein on the PKR-eIF2alpha pathway in RK13 and HeLa cells. Virology 2009; 394(1): 73-81.
27. Willis KL, Langland JO, Shisler JL. Viral dsRNAs from vaccinia virus early or intermediate gene transcripts possess PKR activating function, resulting in NF-{kappa}B activation, when the K1 protein is absent or mutated. J Biol Chem 2011; 286: 7765-7778.
28. Meng X, Jiang C, Arsenio J, Dick K, Cao J, Xiang Y. Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons. J Virol 2009; 83(20): 10627-10636.
29. Moss B. Poxviridae: the viruses and their replication. In Fields Virology, 5th edn Edited by DM Knipe & PM Howley Philadelphia: Wolters Kluwer Health /Lippincott Williams & Wilkins 2007: 2905-2946.
30. Tolonen N, Doglio L, Schleich S, Krijnse Locker J. Vaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nuclei. Mol Biol Cell 2001; 12(7): 2031-2046.
31. Moss B. Poxvirus entry and membrane fusion. Virology 2006; 344(1): 48-54.
32. Tartaglia J, Cox WI, Pincus S, Paoletti E. Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC. Dev Biol Stand 1994; 82: 125-129.
33. Tartaglia J, Cox WI, Taylor J, et al. Highly attenuated poxvirus vectors. AIDS Res Hum Retroviruses 1992; 8(8): 1445-1447.
34. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998; 79(Pt 2): 347-352.
35. Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997; 238(2): 198-211.
36. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992; 89(22): 10847-1051.
37. Guerra S, Lopez-Fernandez LA, Pascual-Montano A, Najera JL, Zaballos A, Esteban M. Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaBresponsive genes in infected HeLa cells. J Virol 2006; 80(2): 985-998.
38. Chahroudi A, Garber DA, Reeves P, Liu L, Kalman D, Feinberg MB. Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J Virol 2006; 80(17): 8469-8481.
39. Guerra S, Lopez-Fernandez LA, Conde R, Pascual-Montano A, Harshman K, Esteban M. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol 2004; 78(11): 5820-5834.
40. Smith GL, Murphy BJ, Law M. Vaccinia virus motility. Annu Rev Microbiol 2003; 57: 323-342.
41. Smith GL, Law M. The exit of vaccinia virus from infected cells. Virus Res 2004; 106(2): 189-197.
42. Ramirez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 2000; 74(2): 923-933.
43. Ramirez JC, Finke D, Esteban M, Kraehenbuhl JP, Acha-Orbea H. Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol 2003; 148(5): 827-839.
44. Corbett M, Bogers WM, Heeney JL, et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci U S A 2008; 105(6): 2046-2051.
45. Finberg RW, Kurt-Jones EA. Viruses and Toll-like receptors. Microbes Infect 2004; 6(15): 1356-1360.
46. Delaloye J, Roger T, Steiner-Tardivel QG, et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 2009; 5(6): e1000480.
47. Seet BT, Johnston JB, Brunetti CR, et al. Poxviruses and immune evasion. Annu Rev Immunol 2003; 21: 377-423.
48. Stack J, Haga IR, Schroder M, et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 2005; 201(6): 1007-1018.
49. Kettle S, Alcami A, Khanna A, Ehret R, Jassoy C, Smith GL. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1betaconverting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. J Gen Virol 1997; 78(Pt 3): 677-685.
50. Perdiguero B, Esteban M. The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 2009; 29(9): 581-598.
51. Isaacs SN, Kotwal GJ, Moss B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci U S A 1992; 89(2): 628-632.
52. Symons JA, Adams E, Tscharke DC, Reading PC, Waldmann H, Smith GL. The vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine intranasal model. J Gen Virol 2002; 83(Pt 11): 2833-2844.
53. Reading PC, Smith GL. Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J Virol 2003; 77(18): 9960-9968.
54. Kluczyk A, Siemion IZ, Szewczuk Z, Wieczorek Z. The immunosuppressive activity of peptide fragments of vaccinia virus C10L protein and a hypothesis on the role of this protein in the viral invasion. Peptides 2002; 23(5): 823-834.
55. Pires de Miranda M, Reading PC, Tscharke DC, Murphy BJ, Smith GL. The vaccinia virus kelch-like protein C2L affects calciumindependent adhesion to the extracellular matrix and inflammation in a murine intradermal model. J Gen Virol 2003; 84(Pt 9): 2459-271.
56. DiPerna G, Stack J, Bowie AG, et al. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NFkappaB and IRF3 signaling by toll-like receptors. J Biol Chem 2004; 279(35): 36570-36578.
57. Cooray S, Bahar MW, Abrescia NG, et al. Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 2007; 88(Pt 6): 1656-1666.
58. Gedey R, Jin XL, Hinthong O, Shisler JL. Poxviral regulation of the host NF-kappaB response: the vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2 pathway in virus-infected human embryonic kidney cells. J Virol 2006; 80(17): 8676-8686.
59. Hinthong O, Jin XL, Shisler JL. Characterization of wild-type and mutant vaccinia virus M2L proteins' abilities to localize to the endoplasmic reticulum and to inhibit NF-kappaB activation during infection. Virology 2008; 373(2): 248-252.
60. Shisler JL, Jin XL. The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation. J Virol 2004; 78(7): 3553-3560.
61. Kawagishi-Kobayashi M, Silverman JB, Ung TL, Dever TE. Regulation of the protein kinase PKR by the vaccinia virus pseudosubstrate inhibitor K3L is dependent on residues conserved between the K3L protein and the PKR substrate eIF2alpha. Mol Cell Biol 1997; 17(7): 4146-4158.
62. Davies MV, Elroy-Stein O, Jagus R, Moss B, Kaufman RJ. The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2. J Virol 1992; 66(4): 1943-1950.
63. Beattie E, Tartaglia J, Paoletti E. Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology 1991; 183(1): 419-422.
64. Davies MV, Chang HW, Jacobs BL, Kaufman RJ. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J Virol 1993; 67(3): 1688-1692.
65. Schroder M, Baran M, Bowie AG. Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J 2008; 27(15): 2147-2157.
66. Wasilenko ST, Banadyga L, Bond D, Barry M. The vaccinia virus F1L protein interacts with the proapoptotic protein Bak and inhibits Bak activation. J Virol 2005; 79(22): 14031-14043.
67. Wasilenko ST, Stewart TL, Meyers AF, Barry M. Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis. Proc Natl Acad Sci U S A 2003; 100(24): 14345-14350.
68. Taylor JM, Quilty D, Banadyga L, Barry M. The vaccinia virus protein F1L interacts with Bim and inhibits activation of the proapoptotic protein Bax. J Biol Chem 2006; 281(51): 39728-39739.
69. Stewart TL, Wasilenko ST, Barry M. Vaccinia virus F1L protein is a tail-anchored protein that functions at the mitochondria to inhibit apoptosis. J Virol 2005; 79(2): 1084-1098.
70. Fischer SF, Ludwig H, Holzapfel J, et al. Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virusassociated apoptosis. Cell Death Differ 2006; 13(1): 109-118.
71. Zhai D, Yu E, Jin C, et al. Vaccinia virus protein F1L is a caspase- 9 inhibitor. J Biol Chem 2010; 285(8): 5569-5580.
72. Froggatt GC, Smith GL, Beard PM. Vaccinia virus gene F3L encodes an intracellular protein that affects the innate immune response. J Gen Virol 2007; 88(Pt 7): 1917-1921.
73. Chang HW, Watson JC, Jacobs BL. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc Natl Acad Sci U S A 1992; 89(11): 4825-4829.
74. Romano PR, Zhang F, Tan SL, et al. Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of complex formation and the E3 N-terminal domain. Mol Cell Biol 1998; 18(12): 7304-7316.
75. Sharp TV, Moonan F, Romashko A, Joshi B, Barber GN, Jagus R. The vaccinia virus E3L gene product interacts with both the regulatory and the substrate binding regions of PKR: implications for PKR autoregulation. Virology 1998; 250(2): 302-315.
76. Liu Y, Wolff KC, Jacobs BL, Samuel CE. Vaccinia virus E3L interferon resistance protein inhibits the interferon-induced adenosine deaminase A-to-I editing activity. Virology 2001; 289(2): 378-387.
77. Smith EJ, Marie I, Prakash A, Garcia-Sastre A, Levy DE. IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or Ikappa B kinase but is blocked by Vaccinia virus E3L protein. J Biol Chem 2001; 276(12): 8951-8957.
78. Xiang Y, Condit RC, Vijaysri S, Jacobs B, Williams BR, Silverman RH. Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J Virol 2002; 76(10): 5251-5259.
79. Guerra S, Caceres A, Knobeloch KP, Horak I, Esteban M. Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog 2008; 4(7): e1000096.
80. Rivas C, Gil J, Melkova Z, Esteban M, Diaz-Guerra M. Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme. Virology 1998; 243(2): 406-414.
81. Langland JO, Kash JC, Carter V, Thomas MJ, Katze MG, Jacobs BL. Suppression of proinflammatory signal transduction and gene expression by the dual nucleic acid binding domains of the vaccinia virus E3L proteins. J Virol 2006; 80(20): 10083-10095.
82. Kwon JA, Rich A. Biological function of the vaccinia virus ZDNA- binding protein E3L: gene transactivation and antiapoptotic activity in HeLa cells. Proc Natl Acad Sci U S A 2005; 102(36):12759-12764.
83. Kim YG, Lowenhaupt K, Oh DB, Kim KK, Rich A. Evidence that vaccinia virulence factor E3L binds to Z-DNA in vivo: Implications for development of a therapy for poxvirus infection. Proc Natl Acad Sci U S A 2004; 101(6): 1514-1518.
84. Garcia MA, Guerra S, Gil J, Jimenez V, Esteban M. Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L. Oncogene 2002; 21(55): 8379-8387.
85. Myskiw C, Arsenio J, van Bruggen R, Deschambault Y, Cao J. Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways. J Virol 2009; 83(13): 6757-6768.
86. Najarro P, Traktman P, Lewis JA. Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation. J Virol 2001; 75(7): 3185-3196.
87. D'Costa SM, Bainbridge TW, Kato SE, Prins C, Kelley K, Condit RC. Vaccinia H5 is a multifunctional protein involved in viral DNA replication, postreplicative gene transcription, and virion morphogenesis. Virology 2010; 401(1): 49-60.
88. Webb TJ, Litavecz RA, Khan MA, et al. Inhibition of CD1d1- mediated antigen presentation by the vaccinia virus B1R and H5R molecules. Eur J Immunol 2006; 36(10): 2595-2600.
89. Liu H, Juo ZS, Shim AH, et al. Structural basis of semaphorinplexin recognition and viral mimicry from Sema7A and A39R complexes with PlexinC1. Cell 2010; 142(5): 749-761.
90. Gardner JD, Tscharke DC, Reading PC, Smith GL. Vaccinia virus semaphorin A39R is a 50-55 kDa secreted glycoprotein that affects the outcome of infection in a murine intradermal model. J Gen Virol 2001; 82(Pt 9): 2083-2093.
91. Walzer T, Galibert L, Comeau MR, De Smedt T. Plexin C1 engagement on mouse dendritic cells by viral semaphorin A39R induces actin cytoskeleton rearrangement and inhibits integrinmediated adhesion and chemokine-induced migration. J Immunol 2005; 174(1): 51-59.
92. Walzer T, Galibert L, De Smedt T. Poxvirus semaphorin A39R inhibits phagocytosis by dendritic cells and neutrophils. Eur J Immunol 2005; 35(2): 391-398.
93. Wilcock D, Duncan SA, Traktman P, Zhang WH, Smith GL. The vaccinia virus A4OR gene product is a nonstructural, type II membrane glycoprotein that is expressed at the cell surface. J Gen Virol 1999; 80 (Pt 8): 2137-2148.
94. Tscharke DC, Reading PC, Smith GL. Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol 2002; 83(Pt 8): 1977-1986.
95. Bahar MW, Kenyon JC, Putz MM, et al. Structure and function of A41, a vaccinia virus chemokine binding protein. PLoS Pathog 2008; 4(1): e5.
96. Ng A, Tscharke DC, Reading PC, Smith GL. The vaccinia virus A41L protein is a soluble 30 kDa glycoprotein that affects virus virulence. J Gen Virol 2001; 82(Pt 9): 2095-2105.
97. Reading PC, Moore JB, Smith GL. Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J Exp Med 2003; 197(10): 1269-1278.
98. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, O'Neill LA. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A 2000; 97(18): 10162-10167.
99. Harte MT, Haga IR, Maloney G, et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 2003; 197(3): 343-351.
100. Maloney G, Schroder M, Bowie AG. Vaccinia virus protein A52R activates p38 mitogen-activated protein kinase and potentiates lipopolysaccharide-induced interleukin-10. J Biol Chem 2005; 280(35): 30838-30844.
101. Alcami A, Khanna A, Paul NL, Smith GL. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J Gen Virol 1999; 80 (Pt 4): 949-959.
102. Beard PM, Froggatt GC, Smith GL. Vaccinia virus kelch protein A55 is a 64 kDa intracellular factor that affects virus-induced cytopathic effect and the outcome of infection in a murine intradermal model. J Gen Virol 2006; 87(Pt 6): 1521-1529.
103. Santos CR, Blanco S, Sevilla A, Lazo PA. Vaccinia virus B1R kinase interacts with JIP1 and modulates c-Jun-dependent signaling. J Virol 2006; 80(15): 7667-7675.
104. Price N, Tscharke DC, Hollinshead M, Smith GL. Vaccinia virus gene B7R encodes an 18-kDa protein that is resident in the endoplasmic reticulum and affects virus virulence. Virology 2000; 267(1): 65-79.
105. Alejo A, Ruiz-Arguello MB, Ho Y, Smith VP, Saraiva M, Alcami A. A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci US 2006; 103(15): 5995-6000.
106. Alcami A, Smith GL. The vaccinia virus soluble interferon-gamma receptor is a homodimer. J Gen Virol 2002; 83(Pt 3): 545-549.
107. Alcami A, Smith GL. Receptors for gamma-interferon encoded by poxviruses: implications for the unknown origin of vaccinia virus. Trends Microbiol 1996; 4(8): 321-326.
108. Mossman K, Upton C, Buller RM, McFadden G. Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 1995; 208(2): 762-769.
109. Symons JA, Tscharke DC, Price N, Smith GL. A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence. J Gen Virol 2002; 83(Pt 8): 1953-19564.
110. Sroller V, Ludvikova V, Maresova L, Hainz P, Nemeckova S. Effect of IFN-gamma receptor gene deletion on vaccinia virus virulence. Arch Virol 2001; 146(2): 239-249.
111. Verardi PH, Jones LA, Aziz FH, Ahmad S, Yilma TD. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity. J Virol 2001; 75(1): 11-18.
112. Dobbelstein M, Shenk T. Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product. J Virol 1996; 70(9): 6479-6485.
113. Smith GL, Howard ST, Chan YS. Vaccinia virus encodes a family of genes with homology to serine proteinase inhibitors. J Gen Virol 1989; 70 (Pt 9): 2333-2343.
114. Chen RA, Jacobs N, Smith GL. Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor. J Gen Virol 2006; 87(Pt 6): 1451-1458.
115. Chen RA, Ryzhakov G, Cooray S, Randow F, Smith GL. Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. PLoS Pathog 2008; 4(2): e22.
116. Spriggs MK, Hruby DE, Maliszewski CR, et al. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 1992; 71(1): 145-152.
117. Alcami A, Smith GL. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 1992; 71(1): 153-167.
118. Waibler Z, Anzaghe M, Frenz T, et al. Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J Virol 2009; 83(4): 1563-1571.
119. Ueda Y, Morikawa S, Matsuura Y. Identification and nucleotide sequence of the gene encoding a surface antigen induced by vaccinia virus. Virology 1990; 177(2): 588-594.
120. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 1995; 270(27): 15974-15978.
121. Alcami A, Symons JA, Smith GL. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 2000; 74(23): 11230-11239.
122. Symons JA, Alcami A, Smith GL. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 1995; 81(4): 551-560.
123. Moon KB, Turner PC, Moyer RW. SPI-1-dependent host range of rabbitpox virus and complex formation with cathepsin G is associated with serpin motifs. J Virol 1999; 73(11): 8999-9010.
124. Guerra S, Najera JL, Gonzalez JM, et al. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol 2007; 81(16): 8707-8721.
125. Gherardi MM, Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 2005; 86(Pt 11): 2925-2936.
126. Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 2004; 3(4 Suppl): S75-S88.
127. Gomez CE, Najera JL, Jimenez EP, et al. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC coexpressing in a single locus the HIV-1BX08 gp120 and HIV- 1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 2007; 25(15): 2863-2885.
128. Gomez CE, Najera JL, Jimenez V, et al. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 2007; 25(11): 1969-1992.
129. Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, et al. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirusbased human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol 2008; 82(6): 2975-2988.
130. Mescher MF, Curtsinger JM, Agarwal P, et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 2006; 211: 81-92.
131. Mescher MF, Agarwal P, Casey KA, Hammerbeck CD, Xiao Z, Curtsinger JM. Molecular basis for checkpoints in the CD8 T cell response: tolerance versus activation. Semin Immunol 2007; 19(3): 153-161.
132. Lu B. The molecular mechanisms that control function and death of effector CD4+ T cells. Immunol Res 2006; 36(1-3): 275-282.
133. Sundrud MS, Rao A. New twists of T cell fate: control of T cell activation and tolerance by TGF-beta and NFAT. Curr Opin Immunol 2007; 19(3): 287-293.
134. Anel A, Bosque A, Naval J, Pineiro A, Larrad L, Alava MA, et al. Apo2L/TRAIL and immune regulation. Front Biosci 2007; 12: 2074-2084.
135. Obst R, van Santen HM, Mathis D, Benoist C. Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response. J Exp Med 2005; 201(10): 1555-1565.
136. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature 2004; 430(6996): 242-249.
137. Fauci AS. Infectious diseases: considerations for the 21st century. Clin Infect Dis 2001; 32(5): 675-685.
138. Sauter SL, Rahman A, Muralidhar G. Non-replicating viral vectorbased AIDS vaccines: interplay between viral vectors and the imimmune system. Curr HIV Res 2005; 3(2): 157-181.
139. Xing Z, Santosuosso M, McCormick S, Yang TC, Millar J, Hitt M, et al. Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines. Curr Gene Ther 2005; 5(5): 485-492.
140. Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology 2006; 344(1): 230-239.
141. Zavala F, Rodrigues M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Esteban M. A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells. Virology 2001; 280(2): 155-159.
142. Nilsson C, Makitalo B, Berglund P, Bex F, Liljestrom P, Sutter G, et al. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 2001; 19(25-26): 3526-3536.
143. Gherardi MM, Najera JL, Perez-Jimenez E, Guerra S, Garcia-Sastre A, Esteban M. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J Virol 2003; 77(12): 7048-7057.
144. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 2005; 102(13): 4836-4841.
145. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23): 2209-2220.
146. Pantaleo G, Esteban M, Jacobs B, Tartaglia J. Poxvirus vectorbased HIV vaccines. Curr Opin HIV AIDS 2010; 5(5): 391-396.
147. Vasan S, Schlesinger SJ, Chen Z, et al. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS One 2010; 5(1): e8816.
148. Sandstrom E, Nilsson C, Hejdeman B, et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008; 198(10): 1482-1490.
149. McCormack S, Stohr W, Barber T, et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008; 26(25): 3162-3174.
150. Harari A, Bart PA, Stohr W, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008; 205(1): 63-77.
151. Esteban M. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum Vaccin 2009; 5(12): 867-871.
152. Berthoud TK, Hamill M, Lillie PJ, et al. Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. Clin Infect Dis 2011; 52(1): 1-7.
153. Scriba TJ, Tameris M, Mansoor N, et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 2010; 40(1): 279-290.
154. Brookes RH, Hill PC, Owiafe PK, et al. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One 2008; 3(8): e2921.
155. Hawkridge T, Scriba TJ, Gelderbloem S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008; 198(4): 544-552.
156. Good MF, Doolan DL. Malaria vaccine design: immunological considerations. Immunity 2010; 33(4): 555-566.
157. Hill AV, Reyes-Sandoval A, O'Hara G, et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010; 6(1): 78-83.
158. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev 2004; 18(19): 2315-2335.
159. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10(8): 789-799.
160. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
161. Bodmer WF, Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG. Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann N Y Acad Sci 1993; 690: 42-49.
162. Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 2003; 52(1): 1-9.
163. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177(2): 265-272.
164. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
165. Botti C, Seregni E, Ferrari L, Martinetti A, Bombardieri E. Immunosuppressive factors: role in cancer development and progression. Int J Biol Markers 1998; 13(2): 51-69.
166. Kiessling R, Wasserman K, Horiguchi S, et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother 1999; 48(7): 353-362.
167. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13(1): 114-119.
168. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296(5566): 301-305.
169. Overwijk WW, Lee DS, Surman DR, et al. Vaccination with a recombinant vaccinia virus encoding a self antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A 1999; 96(6): 2982-2987.
170. Carroll MW, Restifo NP. Cancer Vaccines and Immunotherapy. Chapter 3. Poxviruses as Vectors for Cancer Immunotherapy. Cambridge, UK: Cambridge University Press; 2000. p. 47-61.
171. Weyer J, Rupprecht CE, Mans J, Viljoen GJ, Nel LH. Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies. Vaccine 2007; 25(21): 4213-4222.
172. Fournillier A, Gerossier E, Evlashev A, et al. An accelerated vaccineschedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo crossreactive T cell responses. Vaccine 2007; 25(42): 7339-7353.
173. Rollier CS, Paranhos-Baccala G, Verschoor EJ, et al. Vaccineinduced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 2007; 45(3): 602-613.
174. Abraham JD, Himoudi N, Kien F, Berland JL, Codran A, Bartosch B, et al. Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine 2004; 22(29-30): 3917-3928.
175. Ba L, Yi CE, Zhang L, Ho DD, Chen Z. Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus. Appl Microbiol Biotechnol 2007; 76(5): 1131-1136.
176. Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, et al. Recombinantmodified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 2005; 79(5): 2678-2688.
177. Czub M, Weingartl H, Czub S, He R, Cao J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 2005; 23(17-18): 2273-2279.
178. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A 2004; 101(17): 6641-6646.
179. Weidinger G, Ohlmann M, Schlereth B, Sutter G, Niewiesk S. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model. Vaccine 2001; 19(20-22): 2764-2768.
180. Zhu Y, Rota P, Wyatt L, Tamin A, Rozenblatt S, Lerche N, et al. Evaluation of recombinant vaccinia virus--measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology 2000; 276(1): 202-213.
181. Stittelaar KJ, Wyatt LS, de Swart RL, Vos HW, Groen J, van Amerongen G, et al. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol 2000; 74(9): 4236-4243.
182. Men R, Wyatt L, Tokimatsu I, Arakaki S, Shameem G, Elkins R, et al. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 2000; 18(27): 3113-3122.
183. Breathnach CC, Clark HJ, Clark RC, Olsen CW, Townsend HG, Lunn DP. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 2006; 24(8): 1180-1190.
184. Breathnach CC, Rudersdorf R, Lunn DP. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Vet Immunol Immunopathol 2004; 98(3-4): 127-136.
185. Wang Z, La Rosa C, Li Z, et al. Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine 2007; 25(6): 1132-1141.
186. Wang Z, La Rosa C, Lacey SF, et al. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J Clin Virol 2006; 35(3): 324-331.
187. Wang Z, La Rosa C, Maas R, et al. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 2004; 78(8): 3965-3976.
188. Stephensen CB, Welter J, Thaker SR, Taylor J, Tartaglia J, Paoletti E. Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC- and ALVACbased CDV recombinants protect against symptomatic infection. J Virol 1997; 71(2): 1506-1513.
189. Paillot R, Ellis SA, Daly JM, et al. Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection. Vaccine 2006; 24(10): 1490-500.
190. Huemer HP, Strobl B, Nowotny N. Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme. Vaccine 2000; 18(14): 1320-1366.
191. Soboll G, Breathnach CC, Kydd JH, Hussey SB, Mealey RM, Lunn DP. Vaccination of ponies with the IE gene of EHV-1 in a recombinant modified live vaccinia vector protects against clinical and virological disease. Vet Immunol Immunopathol 2010; 135(1-2): 108-117.
192. Olszewska W, Suezer Y, Sutter G, Openshaw PJ. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine 2004; 23(2): 215-221.
193. de Waal L, Wyatt LS, Yuksel S, et al. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine 2004; 22(8): 923-96.
194. Wyatt LS, Whitehead SS, Venanzi KA, Murphy BR, Moss B. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 1999; 18(5-6): 392-397.
195. Antonis AF, van der Most RG, Suezer Y, et al. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge. Vaccine 2007; 25(25): 4818-4827.
196. Nam JH, Bang HS, Cho HW, Chung YH. Different contribution of co-stimulatory molecules B7.1 and B7.2 to the immune response to recombinant modified vaccinia virus ankara vaccine expressing prM/E proteins of Japanese encephalitis virus and two hepatitis B virus vaccines. Acta Virol 2007; 51(2): 125-1230.
197. Nam JH, Cha SL, Cho HW. Immunogenicity of a recombinant MVA and a DNA vaccine for Japanese encephalitis virus in swine. Microbiol Immunol 2002; 46(1): 23-28.
198. Nam JH, Wyatt LS, Chae SL, Cho HW, Park YK, Moss B. Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes. Vaccine 1999; 17(3): 261-268.
199. Raengsakulrach B, Nisalak A, Gettayacamin M, et al. Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC- JEV recombinant Japanese encephalitis vaccines in rhesus monkeys. Am J Trop Med Hyg 1999; 60(3): 343-349.
200. Konishi E, Pincus S, Paoletti E, Laegreid WW, Shope RE, Mason PW. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology 1992; 190(1): 454-458.
201. Kreijtz JH, Suezer Y, van Amerongen G, d et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 2007; 195(11): 1598-1606.
202. Bender BS, Rowe CA, Taylor SF, Wyatt LS, Moss B, Small PA, Jr. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 1996; 70(9): 6418-6424.
203. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994; 12(11): 1032-1040.
204. Kreijtz JH, Suezer Y, de Mutsert G, et al. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 2009; 27(45): 6296-6299.
205. Kreijtz JH, Suezer Y, de Mutsert G, et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 2009; 199(3): 405-413.
206. Kyriakis CS, De Vleeschauwer A, Barbe F, Bublot M, Van Reeth K. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine 2009; 27(16): 2258-2264.
207. Hessel A, Schwendinger M, Fritz D, et al. A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations. PLoS One 2010; 5(8): e12217.
208. Kreijtz JH, Suzer Y, Bodewes R, et al. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J Gen Virol 2010; 91(Pt 11): 2745-2752.
209. Williams A, Goonetilleke NP, McShane H, et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun 2005; 73(6): 3814-3816.
210. Vordermeier HM, Rhodes SG, Dean G, et al. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology 2004; 112(3): 461-470.
211. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003; 171(3): 1602-1609.
212. Feng CG, Blanchard TJ, Smith GL, Hill AV, Britton WJ. Induction of CD8+ T-lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus. Immunol Cell Biol 2001; 79(6): 569-575.
213. Verreck FA, Vervenne RA, Kondova I, et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 2009; 4(4): e5264.
214. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 2009; 77(8): 3364-3373.
215. Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankarabased tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clin Vaccine Immunol 2010; 17(5): 793-801.
216. Roque-Resendiz JL, Rosales R, Herion P. MVA ROP2 vaccinia virus recombinant as a vaccine candidate for toxoplasmosis. Parasitology 2004; 128(Pt 4): 397-405.
217. Zhang G, Huong VT, Battur B, et al. A heterologous prime-boost vaccination regime using DNA and a vaccinia virus, both expressing GRA4, induced protective immunity against Toxoplasma gondii infection in mice. Parasitology 2007; 134(Pt 10): 1339-1346.
218. Stober CB, Lange UG, Roberts MT, Alcami A, Blackwell JM. Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes longterm memory against Leishmania major in susceptible BALB/c Mice. Infect Immun 2007; 75(2): 852-860.
219. Perez-Jimenez E, Kochan G, Gherardi MM, Esteban M. MVALACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect 2006; 8(3): 810-822.
220. Dondji B, Perez-Jimenez E, Goldsmith-Pestana K, Esteban M, McMahon-Pratt D. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun 2005; 73(8): 5286-5289.
221. Ramos I, Alonso A, Marcen JM, et al. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 2008; 26(3): 333-344.
222. Carson C, Antoniou M, Ruiz-Arguello MB, et al. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine 2009; 27(7): 1080-1086.
223. Cebere I, Dorrell L, McShane H, et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006; 24(4): 417-425.
224. Peters BS, Jaoko W, Vardas E, et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 2007; 25(11): 2120-2127.
225. Goonetilleke N, Moore S, Dally L, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a primeboost regimen of DNA- and modified vaccinia virus Ankaravectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 2006; 80(10): 4717-4728.
226. Mwau M, Cebere I, Sutton J, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004; 85(Pt 4): 911-919.
227. Bart PA, Goodall R, Barber T, et al. EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 2008; 26(25): 3153-3161.
228. Aboud S, Nilsson C, Karlen K, et al. Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes. Clin Vaccine Immunol 2010; 17(7): 1124-1131.
229. Currier JR, Ngauy V, de Souza MS, et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 2010; 5(11): e13983.
230. Ramanathan VD, Kumar M, Mahalingam J, et al. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses 2009; 25(11): 1107-1116.
231. Vollmar J, Arndtz N, Eckl KM, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006; 24(12): 2065-2070.
232. Cosma A, Nagaraj R, Staib C, et al. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res Hum Retroviruses 2007; 23(6): 782-793.
233. Frey SE, Newman FK, Kennedy JS, et al. Clinical and immunologic responses to multiple doses of IMVAMUNE((R)) (Modified Vaccinia Ankara) followed by Dryvax((R)) challenge. Vaccine 2007.
234. Konishi E, Kurane I, Mason PW, et al. Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates. Vaccine 1998; 16(8): 842-849.
235. Kanesa-thasan N, Smucny JJ, Hoke CH, et al. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinianonimmune and vaccinia-immune humans. Vaccine 2000; 19(4-5): 483-491.
236. Bejon P, Mwacharo J, Kai OK, et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 2006; 24(22): 4709-4715.
237. Walther M, Thompson FM, Dunachie S, et al. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun 2006; 74(5): 2706-2716.
238. Dunachie SJ, Walther M, Vuola JM, et al. A clinical trial of primeboost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 2006; 24(15): 2850-2859.
239. Dunachie SJ, Walther M, Epstein JE, et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondinrelated adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006; 74(10): 5933-5942.
240. Moorthy VS, Imoukhuede EB, Milligan P, et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA METRAP against malaria infection in Gambian adults. PLoS Med 2004; 1(2): e33.
241. McConkey SJ, Reece WH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9(6): 729-735.
242. Ockenhouse CF, Sun PF, Lanar DE, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998; 177(6): 1664-1673.
243. McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10(11): 1240-1244.
244. Ibanga HB, Brookes RH, Hill PC, et al. Early clinical trials with anew tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. Lancet Infect Dis 2006; 6(8): 522-528.
245. Espenschied J, Lamont J, Longmate J, et al. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 2003; 170(6): 3401-3407.
246. Daftarian P, Song GY, Ali S, et al. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res 2004; 64(15): 5407-5414.
247. Song GY, Gibson G, Haq W, et al. An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunol Immunother 2007; 56(8): 1193-1205.
248. Ishizaki H, Song GY, Srivastava T, et al. Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. J Immunother 2010; 33(6): 609-617.
249. Hodge JW, Poole DJ, Aarts WM, Gomez Yafal A, Gritz L, Schlom J. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res 2003; 63(22): 7942-7949.
250. Mulryan K, Ryan MG, Myers KA, et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther 2002; 1(12): 1129-1137.
251. Harrop R, Ryan MG, Myers KA, Redchenko I, Kingsman SM, Carroll MW. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol Immunother 2006; 55(9): 1081-1090.
252. Ishizaki H, Manuel ER, Song GY, Srivastava T, Sun S, Diamond DJ, et al. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother 2011; 60(1): 99-109.
253. Krupa M, Canamero M, Gomez CE, Najera JL, Gil J, Esteban M. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine 2011; 29(7); 1504-1513.
254. Valdez Graham V, Sutter G, Jose MV, et al. Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus. Cancer 2000; 88(7): 1650-1662.
255. Rosales C, Graham VV, Rosas GA, Merchant H, Rosales R. A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibodydependent cytotoxicity. Cancer Immunol Immunother 2000; 49(7): 347-360.
256. Mackova J, Kutinova L, Hainz P, et al. Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12. Int J Oncol 2004; 24(6): 1581-1588.
257. Mackova J, Stasikova J, Kutinova L, et al. Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara. Cancer Immunol Immunother 2006; 55(1): 39-46.
258. Nemeckova S, Smahel M, Hainz P, et al. Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules. Neoplasma 2007; 54(4): 326-333.
259. Paul S, Regulier E, Rooke R, et al. Tumor gene therapy by MVAmediated expression of T-cell-stimulating antibodies. Cancer Gene Ther 2002; 9(5): 470-477.
260. Paul S, Regulier E, Poitevin Y, Hormann H, Acres RB. The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer. Cancer Immunol Immunother 2002; 51(11-12): 645-654.
261. Erbs P, Findeli A, Kintz J, et al. Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther 2008; 15(1): 18-28.
262. Odin L, Favrot M, Poujol D, et al. Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53. Cancer Gene Ther 2001; 8(2): 87-98.
263. Jourdier TM, Moste C, Bonnet MC, et al. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther 2003; 10(26): 2126-2132.
264. Sivanandham M, Shaw P, Bernik SF, Paoletti E, Wallack MK. Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice. Cancer Immunol Immunother 1998; 46(5): 261-267.
265. Meyer RG, Britten CM, Siepmann U, et al. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother 2005; 54(5): 453-467.
266. Di Nicola M, Carlo-Stella C, Mortarini R, et al. Boosting T cellmediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Clin Cancer Res 2004; 10(16): 5381-5390.
267. Smith CL, Dunbar PR, Mirza F, et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 2005; 113(2): 259-266.
268. Dangoor A, Lorigan P, Keilholz U, et al. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother 2010; 59(6): 863-873.
269. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003; 5(8): 690-699.
270. Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 2008; 3(7): 735-744.
271. Oudard S, Rixe O, Beuselinck B, et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 2011; 60(2): 261-271.
272. Dreicer R, Stadler WM, Ahmann FR, et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 2009; 27(4): 379-386.
273. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006; 12(11 Pt 1): 3416-3424.
274. Elkord E, Dangoor A, Drury NL, et al. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother 2008; 31(9): 820-829.
275. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007; 13(15 Pt 1): 4487-4494.
276. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 2008; 57(7): 977-986.
277. Kaufman HL, Taback B, Sherman W, et al. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med 2009; 7: 2.
278. Hawkins RE, Macdermott C, Shablak A, et al. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon- alpha. J Immunother 2009; 32(4): 424-429.
279. Amato RJ, Shingler W, Goonewardena M, et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother 2009; 32(7): 765-772.
280. Amato RJ, Shingler W, Naylor S, et al. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase I trial. Clin Cancer Res 2008; 14(22): 7504-7510.
281. Amato RJ, Hawkins RE, Kaufman HL, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, doubleblind, placebo-controlled phase III study. Clin Cancer Res 2010; 16(22): 5539-5547.
282. Amato RJ, Drury N, Naylor S, et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 2008; 31(6): 577-585.
283. Corona Gutierrez CM, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004; 15(5): 421-431.
284. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006; 13(6): 592-597.
285. Albarran YCA, de la Garza A, Cruz Quiroz BJ, et al. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. BioDrugs 2007; 21(1): 47-59.
286. Palmowski MJ, Choi EM-L, Hermans IF, et al. Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols. J Immunol 2002; 168(9): 4391-4398.
287. Hawkins RE, Dangoor A, Keilholz U, et al. Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. J Clin Oncol (Meeting Abstracts) 2006; 24(18_suppl): 8030.
288. Liu M, Acres B, Balloul JM, et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 2004; 101 Suppl 2: 14567-14571.
289. Banu E, Rixe O, Linassier C, et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2006; 24(18_suppl): 2581.
290. Dreicer R, Ahman R, Pantuck A, et al. Vaccine immunotherapy with MVA-Muc1-IL2 (TG4010) in prostate cancer patients with biochemical failure. J Clin Oncol (Meeting Abstracts) 2005; 23(16_suppl): 4518.
291. Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther 2005; 5(6): 619-628.
292. Thorne SH, Bartlett DL, Kirn DH. The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr Gene Ther 2005; 5(4): 429-443.
293. Zeh HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther 2002; 9(12): 1001-1012.
294. Staib C, Kisling S, Erfle V, Sutter G. Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol 2005; 86(Pt 7): 1997-2006.
295. Cottingham MG, Andersen RF, Spencer AJ, et al. Recombinationmediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One 2008; 3(2): e1638.
296. Garcia-Arriaza J, Najera JL, Gomez CE, Sorzano CO, Esteban M. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One 2010; 5(8): e12395.
297. Abaitua F, Rodriguez JR, Garzon A, Rodriguez D, Esteban M. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res 2006; 116(1-2): 11-20.
298. Gomez CE, Najera JL, Sanchez R, Jimenez V, Esteban M. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Vaccine 2009; 27(24): 3165-3174.
299. Najera JL, Gomez CE, Garcia-Arriaza J, Sorzano CO, Esteban M. Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One 2010; 5(6): e11406.